Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 49, 2015, Pages 15136-15141

  Saigusa, Ryosuke ^a   Asano, Yoshihide ^a   Taniguchi, Takashi ^a   Yamashita, Takashi ^a   Ichimura, Yohei ^a   Takahashi, Takehiro ^a   Toyama, Tetsuo ^a   Yoshizaki, Ayumi ^a   Sugawara, Koji ^b   Tsuruta, Daisuke ^b   Taniguchi, Tadatsugu ^c,d   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c INSTITUTE OF INDUSTRIAL SCIENCE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Fibrosis; Interferon regulatory factor 5; Systemic sclerosis; Toll like receptor 4; Vasculopathy

Indexed keywords

BLEOMYCIN; INTERFERON REGULATORY FACTOR 5; TOLL LIKE RECEPTOR 4; INTERFERON REGULATORY FACTOR; IRF5 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL TO MESENCHYMAL TRANSITION; FEMALE; HUMAN; INFLAMMATORY CELL; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TH17 CELL; TH2 CELL; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; B-LYMPHOCYTES; FEMALE; INTERFERON REGULATORY FACTORS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SCLERODERMA, SYSTEMIC; TOLL-LIKE RECEPTOR 4;

EID: 84949267033     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1520997112     Document Type: Article

References (32)

1. Asano Y, Sato S (2015) Vasculopathy in scleroderma. Semin Immunopathol 37(5): 489-500.
2. Arnett FC, et al. (2001) Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 44(6): 1359-1362.
3. Feghali-Bostwick C, Medsger TA, Jr, Wright TM (2003) Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 48(7):1956-1963.
4. Broen JC, Radstake TR, Rossato M (2014) The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol 10(11):671-681.
5. Bhattacharyya S, et al. (2013) Toll-like receptor 4 signaling augments transforming growth factor-β responses: A novel mechanism for maintaining and amplifying fi-brosis in scleroderma. Am J Pathol 182(1):192-205.
6. Bhattacharyya S, et al. (2014) FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med 6(232):232ra50.
7. Takahashi T, et al. (2015) Amelioration of tissue fibrosis by toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheumatol 67(1):254-265.
8. Yoshizaki A, et al. (2009) Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: Association with disease severity. J Clin Immunol 29(2):180-189.
9. Yoshizaki A, et al. (2008) Clinical significance of serum hyaluronan levels in systemic sclerosis: Association with disease severity. J Rheumatol 35(9):1825-1829.
10. Dieudé P, et al. (2009) Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: A new perspective for pulmonary fibrosis. Arthritis Rheum 60(1):225-233.
11. Ito I, et al. (2009) Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 60(6):1845-1850.
12. Dieude P, et al. (2010) Phenotype-haplotype correlation of IRF5 in systemic sclerosis: Role of 2 haplotypes in disease severity. J Rheumatol 37(5):987-992.
13. Radstake TR, et al.; Spanish Scleroderma Group (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42(5):426-429.
14. Tang L, Chen B, Ma B, Nie S (2014) Association between IRF5 polymorphisms and autoimmune diseases: A meta-analysis. Genet Mol Res 13(2):4473-4485.
15. Allanore Y, et al. (2011) Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet 7(7):e1002091.
16. Honda K, Taniguchi T (2006) IRFs: Master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6(9):644-658.
17. Takaoka A, et al. (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434(7030):243-249.
18. Noda S, et al. (2014) Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun 5:5797.
19. Yang H, Antoine DJ, Andersson U, Tracey KJ (2013) The many faces of HMGB1: Molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 93(6):865-873.
20. Negishi H, et al. (2012) Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat Immunol 13(7):659-666.
21. Reynolds JM, Martinez GJ, Chung Y, Dong C (2012) Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci USA 109(32):13064-13069.
22. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF (2004) Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 41(12): 1123-1133.
23. Asano Y, et al. (2010) Endothelial Fli1 deficiency impairs vascular homeostasis: A role in scleroderma vasculopathy. Am J Pathol 176(4):1983-1998.
24. Sharif R, et al. (2012) IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. Ann Rheum Dis 71(7):1197-1202.
25. Taniguchi T, et al. (2015) Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Arthritis Rheumatol 67(2):517-526.
26. Jimenez SA (2013) Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis. ISRN Rheumatol 2013:835948.
27. Murad S (2014) Toll-like receptor 4 in inflammation and angiogenesis: A double-edged sword. Front Immunol 5:313.
28. Yang S, Xu L, Yang T, Wang F (2014) High-mobility group box-1 and its role in an-giogenesis. J Leukoc Biol 95(4):563-574.
29. Yoshizaki A, et al. (2010) Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 185(4): 2502-2515.
30. O'Reilly S, Cant R, Ciechomska M, van Laar JM (2013) Interleukin-6: A new therapeutic target in systemic sclerosis? Clin Transl Immunology 2(4):e4.
31. Rincón M, Anguita J, Nakamura T, Fikrig E, Flavell RA (1997) Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 185(3):461-469.
32. Asano Y, et al. (2006) Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis. Rheumatology (Oxford) 45(3):303-307.